# To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

> **NCT06072131** · PHASE3 · RECRUITING · sponsor: **Acrotech Biopharma Inc.** · enrollment: 504 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Belinostat Injection
- **DRUG:** Pralatrexate Injection
- **DRUG:** CHOP
- **DRUG:** COP

## Key facts

- **NCT ID:** NCT06072131
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-04
- **Primary completion:** 2030-07
- **Final completion:** 2030-11
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072131, "To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06072131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*